GSK and Alector halted the phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226), an anti-sortilin 1 antibody, after an interim futility analysis showed it was unlikely to meet the primary endpoint of slowing disease progression in early Alzheimer's patients. 1 The trial involved 367 participants randomized to one of two doses or placebo; the drug aimed to elevate progranulin levels to support brain neurons and microglia. 1 This failure marks the second setback for the 2021 GSK-Alector partnership, which included a $700M upfront payment, following latozinemab's phase 3 failure in frontotemporal dementia. 1 5 Analysts at TD Cowen state the result effectively ends the GSK-Alector partnership. 1 Alector's prior AbbVie-partnered Alzheimer's candidate also failed in 2024. 1 Sources: 1. https://www.fiercebiotech.com/biotech/gsks-700m-alector-bet-blows-alzheimers-drug-flunks-phase-2 5. https://lifescivoice.com/alector-latozinemab-development-failure-ftd/
- Get link
- X
- Other Apps